EnBiotix

About:

EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.

Website: http://enbiotix.com/

Twitter/X: EnBiotix

Top Investors: Cystic Fibrosis Foundation, Vectura, Apeiron Holdings Limited, Sanford Biosciences, Wired Holdings

Description:

EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.